Inclusion Criteria:
  1. Patients evaluated for residual or recurrent gliomas after initial tumor surgery, external beam radiation and / or chemotherapy with temozolamide.
  2. Male and female
  3. Ages 18 to 70
Exclusion Criteria:
  1. Patient diagnosis with glioma but before surgery, external beam radiation and /or chemotherapy with temozolamide.
  2. Women who were pregnant, breast feeding, or possibly pregnant.
  3. Patients with hepatic or renal dysfunction.
  4. Patients with MRI contraindications (i.e. pacemakers, non-MR compatible devices).
  5. Patients with a history of drug hypersensitivity to 18F-Fluciclovine.